Sanofi's search for a new CEO to replace Olivier Brandicourt, who has decided to retire, has ended with the appointment of Paul Hudson, head of pharma at Novartis AG, to its top post.
Hudson To Succeed Brandicourt As Sanofi CEO
All change at the top for Sanofi which has poached Novartis pharma chief Paul Hudson to succeed Olivier Brandicourt as CEO.
More from Leadership
More from Scrip
• By
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.